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BIPHASIC RELEASE OF SECRETORY PHOSPHOLIPASE A2 DURING AND AFTER
CARDIOPULMONARY BYPASS
Peter Bruins, MD,a Henk te Velthuis, PhD,b Piet G. M. Jansen, MD, PhD,c Leo´n Eijsman, MD, PhD,c and
C. Erik Hack, MD, PhD,b Amsterdam, The Netherlands
Recently Nakamura and colleagues1 reported on the
enhancement of secretory phospholipase A2 (sPLA2) ac-
tivity during cardiac operations. sPLA2 activity increased
after systemic heparinization, before the patient was con-
nected to the extracorporeal circuit, and was partially
reduced after protamine administration. PLA2 hydrolyses
the sn-2-ester bond of phospholipids and catalyzes the
rate-limiting step in the formation of eicosanoids from
membranes. Consistent herewith, Nakamura and col-
leagues1 showed that sPLA2 activity correlated with the
generation of circulating 6-keto-prostaglandin F1a during
cardiac surgery and concluded that systemic hepariniza-
tion stimulates eicosanoid production, which contributes
to the vasodilating and anticoagulant action of heparin
during cardiopulmonary bypass (CPB). However, cyto-
kines such as interleukin-1b, interleukin-6, and tumor
necrosis factor-a also stimulate the production of sPLA2
by cells including neutrophils, platelets, endothelial cells,
and liver cells. The regulatory sequences of the sPLA2
gene contain a putative interleukin-6 responsive element,
homologous to that found in several acute-phase genes.2
Hence sPLA2 may be an acute-phase protein. The acute-
phase response is a sequential series of events that are
induced by proinflammatory cytokines. An acute-phase
response is clinically marked by leukocytosis, fever, met-
abolic changes, and increased (but also decreased) syn-
thesis of various liver proteins. The physiologic impor-
tance of this response is unknown. The first acute-phase
proteins to rise during the acute-phase response are
sPLA2 and C-reactive protein (CRP). We studied the
release of sPLA2 not only during CPB but also during the
acute-phase reaction induced by this procedure.
Methods. We studied the release of sPLA2 and CRP in
10 patients, seven men and three women aged 58 years
(range 54 to 67 years) and weighing 82 kg (range 79 to 91
kg) scheduled to undergo elective coronary artery bypass
grafting. The study was approved by the Medical Ethics
Committee of the Academic Medical Centre of Amster-
dam and written informed consent was obtained from
each patient. Anesthesia and surgical procedure were
standardized and identical for all patients. In brief, on the
morning of the operation, patients received their usual
dose of antianginal drugs and lorazepam (2 to 4 mg) as
premedication. Anesthesia was induced intravenously
with etomidate (0.2 mg/kg), fentanyl (50 mg/kg), pancuro-
nium bromide (0.1 mg/kg), and midazolam (0.1 mg/kg)
and maintained by supplemental doses. After endotra-
cheal intubation, patients were ventilated to normocapnia
with oxygen and air mixture. Cefamandole (2 gm) was
given intravenously for infection prophylaxis. A radial
artery catheter and a flow-directed pulmonary artery
catheter (Swan-Ganz, Baxter/American Edwards Labora-
tories, Santa Ana, Calif.) were inserted for hemodynamic
measurements and collection of blood samples. Volume
was supplemented and further deviations from pressures
or vascular resistances were treated with appropriate
vasoactive medication. The extracorporeal circuit con-
sisted of a hollow-fiber oxygenator with integrated heat
exchanger (Univox, Baxter Healthcare Corp., Irvine, Cal-
if.) and roller pump. CPB duration was 93 minutes (80 to
111 minutes). Heparinization was identical for both
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groups (250 U/kg body weight, Leo Pharmaceutical Prod-
ucts, Weesp, The Netherlands). Blood samples were col-
lected from the radial artery catheter or the arterial site of
the extracorporeal circuit and by venous puncture after
removal of the radial artery catheter. Platelet-poor plasma
was prepared by centrifugation immediately after collec-
tion and stored at –70° C. Circulating concentrations of
PLA2 and CRP were determined with enzyme-linked
immunosorbent assays as previously described.3
Results. Consistent with the data of Nakamura and
coworkers,1 we found significant increases, that is, up to
threefold the baseline levels, of sPLA2 during CPB (Fig.
1). However, levels increased tremendously, that is, up to
thirty times baseline levels, on the first and second post-
operative days. To demonstrate that sPLA2 release during
CPB is induced by systemic heparin, we incubated 0.2 ml
of whole blood of a healthy volunteer in phosphate-
buffered saline solution containing increasing heparin
(Leo Pharmaceutical Products) concentrations for 15
minutes at room temperature on a shaker (200 rpm).
Heparin at a concentration of 3 U/ml, comparable with
that during systemic heparinization, caused a 2.5-fold
increase (60.55, standard deviation) of sPLA2 from blood
cells and reached a maximal 4.1-fold increase (60.81) at
25 U/ml (Fig. 2). These in vitro data also suggest that the
elevations of sPLA2 during CPB are mainly explained by
heparinization of the patient.
Comment. The elevation on the postoperative days
likely reflected that sPLA2 is an acute-phase protein, as
stated previously.2-4 Its production and release continued
for several days while preceding the release of the proto-
type of acute-phase proteins in man, CRP. The role of
sPLA2 in the acute-phase response in general and after
cardiac surgery more specifically is not clear. It has been
hypothesized that sPLA2 and CRP, in a combined effort,
promote phagocytosis of injured cells and tissue debris by
neutrophils. The molecular base for this hypothesis is that
sPLA2 preferentially hydrolyzes phospholipids of cells
that have undergone a flip-flop (i.e., an exchange of
phospholipids of the inner and outer leaflet of the plasma
membrane, for example, as a consequence of ischemia) to
generate binding sites for CRP. Bound CRP in turn may
induce complement activation via the classical pathway
and so promote phagocytosis of metabolically compro-
mised cells that are generated during inflammation or
ischemia.4 During cardiac surgery, the tissues of heart and
lungs especially are deprived of oxygen during aortic
crossclamping and may therefore be the primary target for
sPLA2 activity, subsequent CRP deposition, and finally
complement- and neutrophil-mediated damage.5 Alterna-
tively, sPLA2 release during the first postoperative day
may further contribute to the generation of proinflamma-
tory prostaglandins and leukotrienes by the mechanism
described by Nakamura and associates.1 Most typical, one
in three patients have rhythm disturbances, mainly atrial
fibrillation with fast ventricular rate, but all patients have
leukocytosis and fever on the first, second, or third
postoperative day.5 Our data suggest that sPLA2 may be
involved in the pathogenesis of these complications.
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Fig. 2. Effect of heparin on the release of secretory
phospholipase A2 levels in whole blood. Whole blood was
incubated with various concentrations of heparin (U/ml)
for 15 minutes at room temperature. Data presented are
medians with range (n 5 3). *p , 0.01 compared with
baseline, Wilcoxon rank-sum test.
Fig. 1. Release of sPLA2 and CRP during and after
cardiac surgery. During heparinization, a minor release of
sPLA2 of threefold baseline levels is found, which is partly
antagonized by the administration of protamine sulfate.
During the acute phase response, a second and major
release of sPLA2 occurs, reaching levels of thirty times
baseline levels. Data presented are medians with inter-
quartile range. *p , 0.01 compared with baseline, Wil-
coxon rank-sum test.
The Journal of Thoracic and
Cardiovascular Surgery
April 1998
9 5 0 Brief communications
release of phospholipase-A2. Cancer Immunol Immunother
1995:41:287-92.
4. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT,
van den Bosch H. A role for secretory phospholipase A2 and
C-reactive protein in the removal of injured cells. Immunol
Today 1997;18:111-5.
5. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PGM, van
Hardevelt FWJ, de Beaumont EMFH, et al. Activation of the
complement system during and after cardiopulmonary bypass
surgery: postsurgery activation involves C-reactive protein and
is associated with postoperative arrhythmia. Circulation 1997;
96:3542-8.
SYNCHRONOUS PATENT FORAMEN OVALE AND BRONCHOPLEURAL FISTULA AFTER RIGHT
PNEUMONECTOMY: NONOPERATIVE MANAGEMENT WITH SURVIVAL
K. Adam Lee, MD, and A. Alan Conlan, MD, Worcester, Mass.
The occurrence of an acute right-to-left shunt after
pneumonectomy has been reported in only 20 cases.
Bronchopleural fistula (BPF) and postpneumonectomy
empyema are common in 2% to 5% of patients, with
mortality ranging between 20% and 70%. Synchronous
patent foramen ovale (PFO) and BPF has not been
reported in the literature. The successful nonoperative
control of these two major postpneumonectomy compli-
cations is described.
A 70-year-old man underwent a right pneumonectomy for
stage II adenocarcinonoma. Preoperative lung function stud-
ies and preoperative blood gas are presented in Table I.
The immediate postpneumonectomy course was com-
plicated by profound hypoxemia noted on the evening of
the operation when the patient was recumbent. The
mediastinum was sharply shifted into the postpneumonec-
tomy space (Fig. 1). The postpneumonectomy drainage
tube was unclamped and air injected to centralize the
mediastinum. This dramatically relieved the hypoxemia,
improving oxygen saturation from 77% to 98% with the
patient breathing 100% oxygen delivered by means of a
face mask. The patient had periods of hypoxia in both the
recumbent position (platypnea) and the upright position
(orthodeoxia), necessitating daily centralization of the
mediastinum.
An echocardiogram revealed an acute intraatrial shunt.
Almost synchronously with the diagnosis of the shunt, the
patient had a paradoxic embolism to the left suboccipital
region that resulted in a right hemianopia.
Symptoms of cough, hemoptysis, and fever developed
on postoperative day 14, and a clinical diagnosis of BPF
was made. The space on the right side was drained with a
chest tube. The BPF was closed temporarily by endoscopic
placement of a felt pledget into the defect, and it was
oversealed with fibrin glue. This resulted in closure of the
BPF with no further air leakage.
Several days later, the interatrial defect was effectively
closed by transvenous placement of a 33 mm double
clamshell device (Nitinol; Boston, Mass.). Symptoms less-
ened immediately, and oxygen saturation returned to
95%. Supplemental oxygen was discontinued and the
closed drainage system of the empyema was converted to
open drainage by a thoracostoma. Subsequent follow-up
examinations at 1, 3, 6, and 8 months show that the BPF
has closed spontaneously.
Discussion. The common causes of dyspnea after pneu-
monectomy are chronic obstructive pulmonary disease,
loss of alveolar volume, pain, restriction of the vascular
bed, and diaphragmatic dysfunction.1 Acute PFO is un-
common and numerous mechanisms for its appearance
have been postulated. The weight of the heart after a right
pneumonectomy causes a shift that pulls the interatrial
septum downward, causing the foramen ovale to open or
widen.2 PFO is found in approximately 20% of postmor-
tem studies in the general public. The heart in this new
position provides a direct course for blood from the
inferior vena cava through the PFO (streaming effect).
Distortion is accentuated in an upright position, creating
an increasing shift of the right atrium and widening the
orifice of the PFO.3 A pressure gradient is created across
the PFO, producing a large shunt and the symptoms of
orthodeoxia and platypnea. Another theory is based on
the anatomic distortion and decreased compliance of the
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Table I. Preoperative pulmonary function test
Actual Predicted %
FVC (L) 4.42 4.37 101
FEV1 (L) 3.22 2.94 110
FEF25%-75% (L/sec) 2.14 2.65 81
FEV1/FVC (%) 73 67 108
MVV (L/min) 132 117 112
Arterial blood gas
values
7.42/32/88/20/96%
FVC, Forced vital capacity; FEV1, forced expiratory volume in 1 second;
FEF, forced expiratory flow; MVV, maximal voluntary ventilation.
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